CorMedix expects to begin repurchasing shares as early as Q1 2026 and had approximately $150 million in cash and cash equivalents, and 79.3 million common shares outstanding as of December 31, 2025.
Zacks Investment Research on MSN
CRMD down 31% in a month: Is this an indication to sell the stock?
Shares of CorMedix CRMD have declined sharply over the past month, reflecting investor concerns following its bearish 2026 ...
“Gout is a form of arthritis in which patients have high levels of a chemical called uric acid in the bloodstream,” explains ...
Methotrexate injection, a treatment for certain autoimmune diseases and cancers, can lead to various side effects. These range from common, mild reactions such as headache and nausea to serious, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results